美國經濟數據｜美國10月CPI按年升2.6%｜核心CPI按年升3.3%　均符預期 – shareandstocks.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity, according to executives on a company conference call held following the approval news. FDA approval and label details Chie Source link

Guggenheim lifted their price objective on Visteon from $134.00 to $143.00 and gave the stock a “buy” rating in a research note on Tuesday. Source link